Karachi: The Searle Company Limited has announced that its Board of Directors will convene a meeting on October 21, 2026, to review and approve the unaudited standalone and consolidated financial statements for the first quarter ending September 30, 2026. This session is set to take place both at the 3rd Floor, One IBL Centre, Shahrah-e-Faisal in Karachi, and through videoconferencing, beginning at 12:30 p.m.

The company has also declared a "Closed Period" from October 15, 2026, to October 21, 2026, inclusive of both dates. During this timeframe, in accordance with clause 5.6.4 of the Rule Book of the Exchange, no Director, CEO, or Executive of The Searle Company Limited is permitted to engage in any transactions involving the company’s shares, either directly or indirectly.

According to information available from the Pakistan Stock Exchange (PSX), these measures are standard protocol for listed companies to ensure transparency and prevent insider trading ahead of significant corporate disclosures. The designated market category for The Searle Company Limited is the pharmaceuticals sector, which continues to be a focal point of investor interest given the industry's critical role in healthcare.

The meeting's outcome will provide insights into the company's financial performance and strategic direction, which are keenly observed by market analysts and investors alike.